Abstract: The present invention relates to methods and compositions to evaluate or assess the response of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies. The invention is based on a determination of the FCGR3A genotype of a subject. The invention can be used for patients with malignancies, particularly lymphoma, and is suited to select best responders and/or adjust treatment condition or protocol for low responders.

Abstract: The present invention relates to methods and compositions to evaluate or assess the response and/or side effects of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response and/or side effects of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies in situations where target neutralisation is desired without depletion of a target cell. The invention is based on a determination of the FCGR3A genotype of a subject. Preferable, the therapeutic antibodies are antibodies or proteins comprising Fc portions of the G4 subclass.